Antihypertensive effect of bopindolol: a multi-centre study.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Hypertension is a prevalent cardiovascular condition requiring effective management.
• Nonselective beta-adrenergic receptor blockers are a cornerstone in hypertension treatment.
• Bopindolol offers a long duration of action and intrinsic sympathomimetic activity.

Purpose of the Study:

• To evaluate the efficacy of varying bopindolol monotherapy doses in patients with essential hypertension.
• To assess the dose-response relationship of bopindolol in reducing blood pressure.

Main Methods:

• A 14-week, single-blind, placebo-controlled trial involving 44 patients with mild to moderate essential hypertension.
• Patients received bopindolol monotherapy, with doses titrated from 1 mg to a maximum of 2 mg daily.
• Blood pressure, heart rate, ECG, and side effects were monitored bi-weekly.

Main Results:

• Bopindolol significantly reduced supine systolic and diastolic blood pressure compared to placebo at 4, 8, and 12 weeks (P < 0.01).
• Supine heart rate was also significantly lowered by bopindolol treatment (P < 0.01).
• Dose-dependent reductions in blood pressure were observed, with the 2 mg dose showing the greatest effect.

Conclusions:

• Bopindolol monotherapy is an effective treatment for essential hypertension.
• The drug demonstrates a favorable safety profile with significant reductions in blood pressure and heart rate.
• Titration of bopindolol dosage allows for effective blood pressure normalization in hypertensive patients.